Antipsychotic prophylaxis is needed after remission from a first psychotic episode in schizophrenia patients: Results from an aborted randomised trial

References

• Davis JM, Janicak PG, Singla A, Sharma RP. Maintenance antipsychotic medication. Barnes T. Antipsychotic drugs and their side-effects. Neuroscience perspectives. London: Academic Press Limited; 1993. 183.
   Google Scholar
• Gilbert PL, Harris MJ, McAdams LA, Jeste DV. Neuroleptic withdrawal in schizophrenic patients. A review of the literature. Arch Gen Psychiatry 1995;52(3):173–88.
   PubMed Web of Science ®Google Scholar
• Gitlin M, Nuechterlein K, Subotnik KL, Ventura J, Mintz J, Fogelson DL . Clinical outcome following neuroleptic discontinuation in patients with remitted recent-onset schizophrenia. Am J Psychiatry 2001;158(11):1835–42.
   PubMed Web of Science ®Google Scholar
• Ram R, Bromet EJ, Eaton WW, Pato C, Schwartz JE. The natural course of schizophrenia: a review of first-admission studies. Schizophr Bull 1992;18(2):185–207.
   PubMed Web of Science ®Google Scholar
• Wiersma D, Nienhuis FJ, Slooff CJ, Giel R. Natural course of schizophrenic disorders: a 15-year followup of a Dutch incidence cohort. Schizophr Bull 1998;24(1):75–85.
   PubMed Web of Science ®Google Scholar
• Crow TJ, MacMillan JF, Johnson AL, Johnstone EC. A randomised controlled trial of prophylactic neuroleptic treatment. Br J Psychiatry 1986;148:120–7.
   PubMed Web of Science ®Google Scholar
• Hogarty GE, Ulrich RF. The limitations of antipsychotic medication on schizophrenia relapse and adjustment and the contributions of psychosocial treatment. J Psychiatr Res 1998;32(3–4):243–50.
   PubMed Web of Science ®Google Scholar
• Kane JM, Rifkin A, Quitkin F, Nayak D, Ramos-Lorenzi J. Fluphenazine vs placebo in patients with remitted, acute first-episode schizophrenia. Arch Gen Psychiatry 1982; 39(1):70–3.
   PubMed Web of Science ®Google Scholar
• McCreadie RG, Wiles D, Grant S, Crockett GT, Mahmood Z, Livingston MG, . The Scottish first episode schizophrenia study. VII. Two-year follow-up. Scottish Schizophrenia Research Group. Acta Psychiatr Scand 1989;80(6):597–602.
   PubMed Web of Science ®Google Scholar
• Lehman AF, Lieberman JA, Dixon LB, McGlashan MPHT, Miller AL, Perkins DO, . Practice guideline for the treatment of patients with schizophrenia. 2nd ed. Am J Psychiatry 2004;161(2 Suppl):1–184.
   PubMed Web of Science ®Google Scholar
• First MB, Gibbon M, Spitzer RL, Williams JB. Structured Clinical Interview for DSM-IV Axis I Disorders–Patient Version (SCID-I/P, Version 2.0). New York: Biometrics Research Department, New York State Psychiatric Institute; 1996.
   Google Scholar
• Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 1987;13(2):261–76.
   PubMed Web of Science ®Google Scholar
• Kay SR, Opler LA, Lindenmayer JP. Reliability and validity of the positive and negative syndrome scale for schizophrenics. Psychiatry Res 1988;23(1):99–110.
   PubMed Web of Science ®Google Scholar
• Chrzanowski WK, Marcus RN, Torbeyns A, Nyilas M, McQuade RD. Effectiveness of long-term aripiprazole therapy in patients with acutely relapsing or chronic, stable schizophrenia: a 52-week, open-label comparison with olanzapine. Psychopharmacology (Berlin) 2006;189(2):259–66.
   PubMed Web of Science ®Google Scholar
• Carpenter WT Jr, Hanlon TE, Heinrichs DW, Summerfelt AT, Kirkpatrick B, Levine J, . Continuous versus targeted medication in schizophrenic outpatients: outcome results. Am J Psychiatry 1990;147(9):1138–48.
   PubMed Web of Science ®Google Scholar
• Hogarty GE, Goldberg SC, Schooler NR, Ulrich RF. Drug and sociotherapy in the aftercare of schizophrenic patients. II. Two-year relapse rates. Arch Gen Psychiatry 1974;31(5):603–8.
   PubMed Web of Science ®Google Scholar
• Dellva MA, Tran P, Tollefson GD, Wentley AL, Beasley CM Jr. Standard olanzapine versus placebo and ineffective-dose olanzapine in the maintenance treatment of schizophrenia. Psychiatr Serv 1997;48(12):1571–7.
   PubMed Web of Science ®Google Scholar
• Engelhardt DM, Rosen B, Freedman N, Margolis R. Phenothiazines in prevention of psychiatric hospitalization. IV. Delay or prevention of hospitalization–a reevaluation. Arch Gen Psychiatry 1967;16(1):98–101.
   PubMed Web of Science ®Google Scholar
• Thompson K, Kulkarni J, Sergejew AA. Reliability and validity of a new Medication Adherence Rating Scale (MARS) for the psychoses. Schizophr Res 2000;42(3):241–7.
   PubMed Web of Science ®Google Scholar
• Kane JM, Leucht S, Carpenter D, Docherty JP. The expert consensus guideline series. Optimizing pharmacologic treatment of psychotic disorders. Introduction: methods, commentary, and summary. J Clin Psychiatry 2003;64(Suppl 12):5–19.
   PubMed Web of Science ®Google Scholar
• van Loenen AC, de Boer JE, Beckeringh JJ, Danz M, van ‘t Hof AJ, Huppes W, . Pharmacotherapeutical compass. van Loenen AC, de Boer JE. Utrecht: Commissie Farmaceutische Hulp van het College voor zorgverzekeringen. Pharmacotherapeutical Compass; 2009.
   Google Scholar
• Pocock SJ. The Size of a clinical trial. Pocock SJ. Clinical trials: A practical approach. Chicester: John Wiley & Sons Ltd; 1983. 129.
   Google Scholar
• Kuipers E, Kendall T. Schizophrenia (update). Antoniou J, Barnes T, Bhui K, Bird V, Brabban A, Flanagan E ., Core interventions in the treatment and management of schizophrenia in primary and secondary care (update). London: National Institute for Health and Clinical Excellence; 2009.
   Google Scholar
• Wunderink L, Nienhuis FJ, Sytema S, Slooff CJ, Knegtering R, Wiersma D. Guided discontinuation versus maintenance treatment in remitted first-episode psychosis: relapse rates and functional outcome. J Clin Psychiatry 2007;68(5):654–61.
   PubMed Web of Science ®Google Scholar
• Iancu I, Dannon PN, Ziv R, Lepkifker E. A follow-up study of patients with DSM-IV schizophreniform disorder. Can J Psychiatry 2002;47(1):56–60.
   PubMed Web of Science ®Google Scholar
• Jager M, Bottlender R, Strauss A, Moller HJ. Fifteen-year follow-up of ICD-10 schizoaffective disorders compared with schizophrenia and affective disorders. Acta Psychiatr Scand 2004;109(1):30–7.
   PubMed Web of Science ®Google Scholar
• Boonstra N, Wunderink L, de Wit PH, Noorthoorn E, Wiersma D. [The administrative incidence of non-affective psychoses in Friesland and Twente]. Tijdschr Psychiatr 2008;50(10):637–43.
   PubMedGoogle Scholar